Kratom carries a real risk of dependence, though it appears to be significantly less addictive than classical opioids like morphine or heroin. In a Johns Hopkins survey of over 2,000 regular kratom users, about 25.5% met the criteria for kratom use disorder. The most common signs were tolerance (needing more to feel the same effect) and withdrawal symptoms when stopping. That places kratom in a middle ground: more habit-forming than many people assume, but less so than the prescription and illicit opioids it’s often compared to.
How Kratom Acts on the Brain
Kratom contains dozens of active compounds, but two do most of the heavy lifting. The primary one, mitragynine, actually blocks the brain’s main opioid receptor rather than activating it, which is the opposite of what morphine does. The second compound, 7-hydroxymitragynine, does activate that same receptor, but only partially, reaching about 41% of the maximum effect that a full activator would produce. This partial activation is a key reason kratom’s “high” and addiction potential fall below those of traditional opioids.
What’s especially interesting is how these compounds affect the brain’s reward circuitry. Classic drugs of abuse, like heroin or cocaine, flood the reward center with dopamine. In mouse studies, mitragynine actually reduced dopamine release in a dose-dependent way. The more potent compound, 7-hydroxymitragynine, increased dopamine at low doses but decreased it at higher ones. Researchers noted that neither compound altered dopamine in a pattern consistent with classic drugs of abuse.
In self-administration studies, where rats can press a lever to dose themselves, animals showed no more interest in mitragynine than they did in saline (essentially water). Mitragynine also reduced how much morphine and heroin rats chose to self-administer. And in brain reward threshold tests, neither of kratom’s main alkaloids showed evidence of rewarding effects, while morphine did so robustly. These findings consistently point to a lower reinforcement potential than traditional opioids.
Who Develops Dependence
Not everyone who uses kratom becomes dependent, but frequency and dose matter considerably. Research from the University of Florida identifies a rough threshold: consuming more than 5 grams per dose, more than three times a day, on a regular basis raises the risk of dependence. That puts kratom in a similar category to caffeine or nicotine in terms of how dependence develops through escalating, habitual use.
In the Johns Hopkins study that assessed over 2,000 kratom consumers using standard diagnostic criteria, about 70.5% showed no signs of a use disorder. Among those who did qualify, 14% had mild symptoms, 7% moderate, and 8.5% severe. The most commonly reported experiences were building tolerance, having withdrawal symptoms, using kratom longer or in larger amounts than planned, and making unsuccessful attempts to cut back.
What Withdrawal Looks Like
Kratom withdrawal is generally described by users and clinicians as mild, tolerable, and self-manageable. Some people report symptoms after going without kratom for just a day or more, but the experience is notably less intense than withdrawal from morphine or heroin. In rat studies comparing the two directly, stopping morphine produced significant signs of spontaneous withdrawal, while stopping mitragynine did not. When withdrawal was chemically triggered in both groups, the kratom-treated animals showed weaker symptoms that resolved more quickly.
Common withdrawal complaints mirror a mild version of opioid withdrawal: think restlessness, irritability, muscle aches, and runny nose rather than the severe cramping, vomiting, and agitation associated with heroin or prescription painkiller withdrawal. For people who do need help managing symptoms, medications typically used for opioid dependence have shown promise. In at least one documented case, a patient was successfully treated with the same medication combination used for opioid addiction, with withdrawal symptoms resolving within the first week of treatment.
Kratom vs. Traditional Opioids
The comparison comes up constantly, and the pharmacology explains why kratom lands in a different category. Mitragynine binds to opioid receptors with roughly 89 times less affinity than morphine or fentanyl. Even 7-hydroxymitragynine, the stronger compound, binds at least 7 times more weakly than those drugs. And because 7-hydroxymitragynine is a partial activator rather than a full one, there’s a ceiling on how much opioid-like effect it can produce.
This translates to real differences in risk. One analysis of survey data concluded that the risk of kratom-associated death was at least a thousand times lower than for morphine-type opioids. In animal models, mitragynine actually reduced morphine and heroin self-administration, and some researchers have explored it as a potential tool for managing opioid withdrawal, similar to how methadone or buprenorphine are used.
That said, 7-hydroxymitragynine does fully mimic morphine’s effects in some tests. In drug discrimination studies, where animals are trained to recognize the feeling of morphine, 7-hydroxymitragynine fully substituted for it. Mitragynine only partially did so. This means kratom products with higher concentrations of 7-hydroxymitragynine, including some concentrated extracts on the market, likely carry a higher addiction risk than plain leaf powder.
Why the Risk Is Hard to Pin Down
One complication is that kratom is an unregulated plant product with highly variable potency. The ratio of mitragynine to 7-hydroxymitragynine differs between strains, batches, and especially between raw leaf and concentrated extracts. Someone drinking brewed kratom tea from dried leaves is getting a very different pharmacological experience than someone taking an extract capsule standardized for 7-hydroxymitragynine.
The FDA has warned consumers about kratom’s risks, including the potential for substance use disorder, liver toxicity, and seizures. The agency has also noted cases of neonatal withdrawal in newborns whose mothers used kratom during pregnancy. No well-designed human abuse potential study has been completed, which means much of what we know about kratom’s addictiveness comes from animal models, user surveys, and case reports rather than the kind of controlled clinical trials that exist for prescription drugs.
The regulatory picture adds another layer of uncertainty. Kratom is not FDA-approved for any use, and there are no standardized kratom products legally marketed in the U.S. It remains legal at the federal level but banned or restricted in several states and municipalities. Without standardization, users have limited ability to control their dose of the specific compounds that drive dependence.
Practical Takeaways on Risk
Kratom is genuinely habit-forming, but for most users, the level of dependence is closer to nicotine or caffeine than to heroin or prescription painkillers. About one in four regular users develops some degree of use disorder, most commonly tolerance and mild withdrawal. The risk climbs with higher doses, more frequent use, and concentrated extract products that contain elevated levels of the more potent alkaloid.
If you’re using kratom occasionally at low doses, the dependence risk is relatively modest. If you’re using it daily at high doses, especially extracts, you’re in the range where tolerance, withdrawal, and difficulty cutting back become common. The gap between “I use this sometimes” and “I need this every day” can close gradually, which is why the most frequently reported symptom among people with kratom use disorder is simply that they used more, and for longer, than they originally planned.